 |
| 13-Jun-13 | Upgrade |
Argus |
Hold → Buy |
$140 |
|
| 26-Apr-13 | Reiterated |
Barclays |
Overweight |
$113 → $132 |
|
| 22-Apr-13 | Reiterated |
Cantor Fitzgerald |
Buy |
$121 → $142 |
|
| 05-Apr-13 | Upgrade |
Deutsche Bank |
Hold → Buy |
$105 → $143 |
|
| 25-Mar-13 | Downgrade |
WallachBeth |
Buy → Hold |
|
|
| 04-Mar-13 | Reiterated |
Cantor Fitzgerald |
Buy |
$115 → $121 |
|
| 12-Feb-13 | Reiterated |
Barclays |
Overweight |
$102 → $111 |
|
| 28-Jan-13 | Downgrade |
Argus |
Buy → Hold |
|
|
| 25-Jan-13 | Reiterated |
Barclays |
Overweight |
$94 → $102 |
|
| 23-Jan-13 | Reiterated |
Stifel Nicolaus |
Buy |
$98 → $108 |
|
| 14-Jan-13 | Reiterated |
Cantor Fitzgerald |
Buy |
$96 → $115 |
|
| 08-Jan-13 | Upgrade |
RBC Capital Mkts |
Sector Perform → Outperform |
$90 → $100 |
|
| 08-Jan-13 | Reiterated |
WallachBeth |
Buy |
$89 → $99 |
|
| 08-Jan-13 | Reiterated |
Stifel Nicolaus |
Buy |
$89 → $98 |
|
| 08-Jan-13 | Reiterated |
Barclays |
Overweight |
$87 → $94 |
|
| 08-Jan-13 | Reiterated |
Argus |
Buy |
$88 → $95 |
|
| 04-Jan-13 | Reiterated |
RBC Capital Mkts |
Sector Perform |
$85 → $90 |
|
| 12-Nov-12 | Reiterated |
Cantor Fitzgerald |
Buy |
$82 → $96 |
|
| 15-Oct-12 | Downgrade |
Oppenheimer |
Outperform → Perform |
|
|
| 21-Sep-12 | Reiterated |
Argus |
Buy |
$75 → $88 |
|
|
|
| 19-Jun-13 05:33AM | IPO Preview: Bluebird Bio at Seeking Alpha |
| 18-Jun-13 06:01PM | Final Glance: Biotechnology companies AP |
| 01:17PM | Midday Glance: Biotechnology companies AP |
| 11:02AM | Dividends, Schmividends at Motley Fool |
| 10:30AM | Good News for Celgene's Pipeline Zacks |
| 10:21AM | Early Glance: Biotechnology companies AP |
| 05:00AM | [video] Drugs IPOs Depend on Deals at TheStreet |
| 12:16AM | [$$] Credits & Debits | cfoeditors@wsj.com at The Wall Street Journal |
| 12:10AM | [$$] Credits & Debits | cfoeditors@wsj.com at The Wall Street Journal |
| 17-Jun-13 10:51PM | [$$] Credits & Debits | cfoeditors@wsj.com at The Wall Street Journal |
| 09:03PM | [$$] Credits & Debits | cfoeditors@wsj.com at The Wall Street Journal |
| 06:46PM | 4 Healthcare Stock Stories Making Waves On Monday at Wall St. Cheat Sheet |
| 06:04PM | Final Glance: Biotechnology companies AP |
| 05:01PM | Celgene Corporation (CELG): Today's Featured Health Care Laggard at TheStreet |
| 01:30PM | Midday Glance: Biotechnology companies AP |
| 10:50AM | Data on BMY/ AbbVie's elotuzumab Zacks |
| 10:40AM | Good News for Celgene's Revlimid Zacks |
| 10:29AM | Early Glance: Biotechnology companies AP |
| 02:32AM | InPlay: Celgene receives EC approval for oral anti-cancer therapy REVLIMID now indicated as a treatment for patients with rare form of blood disease Briefing.com |
| 01:30AM | Oral Anti-Cancer Therapy REVLIMID® (lenalidomide) Now Indicated as a Treatment for Patients with Rare Form of Blood Disease Business Wire |
| 14-Jun-13 06:03PM | Final Glance: Biotechnology companies AP |
| 02:34PM | Analysts: Facebook Transitions Could Spur Risks and 3 More Research Notes to Browse at Wall St. Cheat Sheet |
| 01:29PM | Threshold Pharmaceuticals: A Biotech That Investors Need To Know About at Motley Fool |
| 01:28PM | Midday Glance: Biotechnology companies AP |
| 12:35PM | Renaissance and insiders like these stocks at MarketWatch |
| 11:00AM | Apremilast Data Presented by Celgene Zacks |
| 10:37AM | Early Glance: Biotechnology companies AP |
| 10:33AM | Stocks Open Mildly Higher; Myriad Continues To Slide at Investor's Business Daily |
| 08:23AM | Celgene multiple likely to expand further, says Cantor theflyonthewall.com |
| 06:10AM | InPlay: Celgene oral Apremilast achieves statistical significance for primary and secondary endpoints in a Phase II Trial in patients with Behcet's disease Briefing.com |
| 06:04AM | Oral Apremilast Achieves Statistical Significance for Primary and Secondary Endpoints in a Phase II Trial in Patients with Behçets Disease Business Wire |
| 13-Jun-13 06:59PM | Myriad's Bearish Dive Shows Biotech Leaders Stalling at Investor's Business Daily |
| 06:59PM | Myriad's Bearish Dive Shows Biotec Leaders Stalling at Investor's Business Daily |
| 06:19PM | 4 Healthcare Stock Stories Getting Notice On Thursday at Wall St. Cheat Sheet |
| 06:03PM | Final Glance: Biotechnology companies AP |
| 04:35PM | Novartis: Drug Pipeline And New Drug Applications at Seeking Alpha |
| 03:45PM | CELG Presents Positive Long-term Data Zacks |
| 02:20PM | Thursday's Top Upgrades (and Downgrades) at Motley Fool |
| 01:34PM | Analysts: MasterCard Volume Is Growing Faster Than Thought and 3 More Research Notes to Read at Wall St. Cheat Sheet |
| 01:17PM | Midday Glance: Biotechnology companies AP |
| 11:13AM | Wal-Marts Shift In Hiring Practices, FedEx Faces Off With the Fed, and 3 More Hot Stocks at Wall St. Cheat Sheet |
| 10:22AM | Early Glance: Biotechnology companies AP |
| 10:08AM | CELGENE CORP /DE/ Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a Vote of S EDGAR Online |
| 09:20AM | Stock Upgrades: Bulls Run on Adidas AG at Minyanville |
| 07:19AM | Bionor Pharma Surges After HIV Drug Study Progress: Oslo Mover at Bloomberg |
| 05:24AM | Celgene presents data from PALACE 3 study theflyonthewall.com |
| 04:36AM | InPlay: Celgene presents data from Phase III randomized controlled study of Apremilast; signs and symptoms in patients with psoriatic arthritis significantly improved with apremilast treatment Briefing.com |
| 04:30AM | Data from Phase III Randomized Controlled Study (PALACE 3) of Apremilast in Psoriatic Arthritis Presented at EULAR Business Wire |
| 01:21AM | Celgene upgraded by Argus Briefing.com |
| 12-Jun-13 10:30PM | Celgene Adds $3 Billion to Buyback Program at Motley Fool |
| 06:11PM | Final Glance: Biotechnology companies AP |
| 05:07PM | Stocks End Near Session Lows; But Rambus Jumps 6% at Investor's Business Daily |
| 04:14PM | Stocks Fall Again As Correction Shows It Has Legs at Investor's Business Daily |
| 03:10PM | Stocks Near Lows In Late Trade; Lululemon Dives Again at Investor's Business Daily |
| 01:38PM | Biogen Stock Dips On Concerns Of MS Drug Protection at Investor's Business Daily |
| 01:17PM | Midday Glance: Biotechnology companies AP |
| 12:58PM | Boeings 787 Woes Return, GE Plays Musical Executives, and 3 More Hot Stocks at Wall St. Cheat Sheet |
| 11:41AM | Celgene reports results for arthritis drug AP |
| 11:38AM | Biogen Tumbles On Citi Downgrade at Barrons.com |
| 11:25AM | 2 More Good Reasons to Buy Celgene at Motley Fool |
| 11:00AM | Warning: This Might Be The Most Overvalued Sector In The Market StreetAuthority Network |
| 11:00AM | Warning: This Might Be The Most Overvalued Sector In The Market |
| 10:47AM | US STOCKS-Wall Street little changed as investors mull policy path at Reuters |
| 10:39AM | Celgene approves stock buyback worth up to $3B AP |
| 10:34AM | Stocks Quietly Pare Gains; Celgene, Nu Skin Rising at Investor's Business Daily |
| 10:32AM | Early Glance: Biotechnology companies AP |
| 09:56AM | Wall Street Rebounds at New York Times |
| 09:56AM | Wall Street Loses Steam at New York Times |
| 09:55AM | Wall Street Rebounds at New York Times |
| 09:23AM | [video] Cramer's Mad Dash: Celgene's Biotech Bounce at CNBC |
| 09:12AM | Wall Street poised for rebound after selloff Reuters |
| 09:12AM | Futures Venture Into Positive Territory; Vodafone, Cooper Tire, Move On M&A News at Barrons.com |
| 09:06AM | US STOCKS-Wall Street poised for rebound after selloff at Reuters |
| 08:03AM | InPlay: Celgene announces additional $3.0 bln share repurchase program Briefing.com |
| 08:02AM | New Data Improves Sales Outlook For Celgene's Apremilast at TheStreet |
| 08:00AM | Celgene Announces Additional $3.0 Billion Share Repurchase Program Business Wire |
| 07:51AM | When It Comes To Biotech, Diversity Is Key at Seeking Alpha |
| 07:38AM | Celgene reports positive Phase III results from psoriatic arhrititis candidate at theflyonthewall.com |
| 07:31AM | InPlay: Celgene: Signs and symptoms of psoriatic arthritis significantly improved in patients receiving long-term oral apremilast treatment in Phase III study (PALACE-1) Briefing.com |
| 07:30AM | Signs and Symptoms of Psoriatic Arthritis Significantly Improved in Patients Receiving Long-Term Oral Apremilast Treatment in Phase III Study (PALACE-1) Business Wire |
| 06:15AM | Zacks Investment Ideas feature highlights: Market Vectors Biotech ETF, iShares Nasdaq Biotechnology ETF, Regeneron, Celgene and First Trust Amex Biotechnology Index Fund Zacks |
| 11-Jun-13 06:07PM | Final Glance: Biotechnology companies AP |
| 06:00PM | J&J's Stelara effective in psoriatic arthritis trial at Reuters |
| 06:00PM | Celgene arthritis drug maintains efficacy at 52 weeks-study at Reuters |
| 01:29PM | [$$] Credits & Debits | cfoeditors@wsj.com at The Wall Street Journal |
| 01:21PM | Midday Glance: Biotechnology companies AP |
| 10:31AM | Early Glance: Biotechnology companies AP |
| 01:00AM | [$$] Credits & Debits | cfoeditors@wsj.com at The Wall Street Journal |
| 12:18AM | [$$] Credits & Debits | cfoeditors@wsj.com at The Wall Street Journal |
| 10-Jun-13 10:56PM | [$$] Credits & Debits | cfoeditors@wsj.com at The Wall Street Journal |
| 09:00PM | [$$] Credits & Debits | cfoeditors@wsj.com at The Wall Street Journal |
| 06:13PM | Agios Pharmaceuticals files for IPO of up to $86 million at Reuters |
| 06:12PM | Agios Pharmaceuticals files for IPO of up to $86 mln at Reuters |
| 06:04PM | Final Glance: Biotechnology companies AP |
| 01:45PM | Celgene Moves Fast And Early In Expanding Its Pipeline at Seeking Alpha |
| 01:19PM | Midday Glance: Biotechnology companies AP |
| 01:03PM | 5 Drugs Stocks Dragging The Industry Down at TheStreet |
| 10:53AM | Celgenes Abraxane: A Therapy for Advanced Pancreatic Cancer? at Motley Fool |
| 09:09AM | TheStreetMONSTER Conference Roundup at TheStreet |
| 07-Jun-13 07:28PM | Many IBD 50 Stocks Show Bullish Action, Find Support at Investor's Business Daily |
|
|
| Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and immune-inflammatory related diseases in the United States, Europe, and other countries. Its commercial stage products include REVLIMID, an oral immunomodulatory drug to treat patients with multiple myeloma and transfusion-dependent anemia; VIDAZA, a pyrimidine nucleoside analog to treat intermediate-2 and high-risk myelodysplastic syndromes (MDS), as well as acute myeloid leukemia (AML); ABRAXANE, a solvent-free chemotherapy treatment option for metastatic breast cancer; and THALOMID for multiple myeloma and the cutaneous manifestations of erythema nodosum leprosum. The company's commercial stage products also comprise ISTODAX to treat cutaneous T-cell lymphoma; POMALYST for the multiple myeloma and myelofibrosis treatment; and FOCALIN, FOCALIN XR, and RITALIN LA products. Its pre clinical and clinical stage products consist of CC-11050, an anti-inflammatory compound; CC-220, an anti-inflammatory product; cellular therapies, such as PDA-001 and PDA-002; CC-486 that is in Phase III trials to treat MDS and AML, as well as in a Phase I trials for the treatment of solid tumor indications; and sotatercept and ACE-536, which are in Phase II trials to treat anemia in patients with blood disorders. The company's pre clinical and clinical stage products also include CC-223, a dual TORK inhibitor; CC-292, a BTK inhibitor; CC-115, a dual TORK/DNA PK inhibitor; CC-122, a pleiotropic pathway modulator; and EPZ-5676, a DOT1L inhibitor. It has strategic collaborations with bluebird bio, Inc. to discover, develop, and commercialize gene therapies in oncology; FORMA Therapeutics Holdings to discover, develop, and commercialize drug candidates to regulate protein homeostasis; and Concert Pharmaceuticals, Inc. to develop deuterium-modified compounds for cancer and inflammation. The company was founded in 1980 and is headquartered in Summit, New Jersey. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| LOUGHLIN JAMES J | Director | Jun 16 | Option Exercise | 0.00 | 685 | 0 | 6,743 | Jun 17 04:13 PM | | HUGIN ROBERT J | see remarks | Jun 16 | Option Exercise | 0.00 | 6,500 | 0 | 513,605 | Jun 17 04:12 PM | | DRAKE RODMAN L | Director | Jun 16 | Option Exercise | 0.00 | 685 | 0 | 19,597 | Jun 17 04:11 PM | | CASEY MICHAEL D | Director | Jun 16 | Option Exercise | 0.00 | 685 | 0 | 2,751 | Jun 17 04:11 PM | | CASEY MICHAEL D | Director | Jun 15 | Option Exercise | 0.00 | 1,033 | 0 | 2,066 | Jun 17 04:11 PM | | DRAKE RODMAN L | Director | Jun 15 | Option Exercise | 0.00 | 1,033 | 0 | 18,912 | Jun 17 04:11 PM | | KAPLAN GILLA | Director | Jun 13 | Option Exercise | 0.00 | 1,033 | 0 | 22,688 | Jun 17 04:13 PM | | Friedman Michael A | Director | Jun 13 | Option Exercise | 0.00 | 1,033 | 0 | 1,033 | Jun 17 04:12 PM | | LOUGHLIN JAMES J | Director | Jun 13 | Option Exercise | 0.00 | 1,033 | 0 | 6,058 | Jun 17 04:13 PM | | MARIO ERNEST | Director | Jun 13 | Option Exercise | 0.00 | 1,033 | 0 | 81,046 | Jun 17 04:14 PM | | DRAKE RODMAN L | Director | Jun 13 | Option Exercise | 0.00 | 516 | 0 | 17,879 | Jun 17 04:11 PM | | BARKER RICHARD W | Director | Jun 13 | Option Exercise | 0.00 | 1,033 | 0 | 1,033 | Jun 17 04:10 PM | | CASEY MICHAEL D | Director | Jun 13 | Option Exercise | 0.00 | 1,033 | 0 | 1,033 | Jun 17 04:11 PM | | MARIO ERNEST | Director | Jun 05 | Option Exercise | 59.89 | 15,000 | 898,350 | 80,013 | Jun 07 04:07 PM | | Celgene European Investment Co | 10% Owner | Jun 05 | Buy | 15.00 | 66,666 | 999,990 | 3,334,640 | Jun 06 03:25 PM | | HUGIN ROBERT J | see remarks | May 30 | Sale | 123.58 | 68,087 | 8,414,001 | 507,105 | May 30 05:32 PM | | HUGIN ROBERT J | see remarks | May 29 | Option Exercise | 31.15 | 378,592 | 11,791,919 | 817,611 | May 30 05:32 PM | | MARIO ERNEST | Director | May 29 | Buy | 123.72 | 1,000 | 123,725 | 65,013 | May 30 07:50 PM | | Daniel Thomas O | see remarks | May 28 | Option Exercise | 60.15 | 32,959 | 1,982,365 | 37,166 | May 30 05:31 PM | | Daniel Thomas O | see remarks | May 28 | Sale | 124.91 | 32,959 | 4,116,764 | 4,207 | May 30 05:31 PM | | CASEY MICHAEL D | Director | Apr 30 | Option Exercise | 11.21 | 9,294 | 104,163 | 9,294 | May 01 04:06 PM | | CASEY MICHAEL D | Director | Apr 30 | Sale | 118.07 | 9,294 | 1,097,354 | 19,458 | May 01 04:06 PM | | DRAKE RODMAN L | Director | Apr 29 | Option Exercise | 38.43 | 1,000 | 38,430 | 17,363 | May 01 04:07 PM | | CASEY MICHAEL D | Director | Apr 29 | Option Exercise | 11.21 | 5,706 | 63,950 | 5,706 | May 01 04:06 PM | | CASEY MICHAEL D | Director | Apr 29 | Sale | 120.11 | 5,706 | 685,323 | 19,458 | May 01 04:06 PM | | DRAKE RODMAN L | Director | Feb 04 | Buy | 98.50 | 400 | 39,399 | 16,363 | Feb 06 04:16 PM | | HUGIN ROBERT J | see remarks | Dec 18 | Option Exercise | 25.68 | 20,172 | 517,916 | 458,298 | Dec 19 06:47 PM | | KAPLAN GILLA | Director | Dec 11 | Option Exercise | 8.41 | 48,000 | 403,440 | 54,055 | Dec 13 04:30 PM | | KAPLAN GILLA | Director | Dec 11 | Sale | 81.42 | 32,400 | 2,637,891 | 21,655 | Dec 13 04:30 PM | | DRAKE RODMAN L | Director | Nov 14 | Option Exercise | 38.43 | 1,000 | 38,430 | 15,963 | Nov 16 04:00 PM | | CASEY MICHAEL D | Director | Jun 22 | Option Exercise | 11.28 | 12,000 | 135,330 | 19,458 | Jun 26 04:17 PM |
|
|
|
|
|
|
